Shots: CELLINK expand the collaboration for 12 months and will provide bioprinters and bioinks for acceleration of the exploration of novel targets in AstraZeneca’s 5 main therapy areas: oncology, respiratory, […]readmore
Tags : Multi-Target
Shots: Sosei Heptares to receive $26M up front, R&D funding, $1.2B+ development & commercial milestones and royalties on sales of the licensed products. Takeda to get WW rights to develop […]readmore
Shots: AbCellera to receive technology access fee, funding, milestones, and royalties on sales of products. Novartis to get rights to license AbCellera’s technology for its 10 unknown targets Additionally, AbCellera […]readmore
Shots: Amgen entered into an agreement with Abilita Bio for the development of therapies utilizing Abilita’s Enabled Membrane Protein (EMP) technology targeting certain integral membrane proteins The focus of the […]readmore